Citi downgrades Crispr Therapeutics to Sell with $21 price target. Citi analyst Yigal downgraded Crispr Therapeutics to Sell from Neutral and cut his price target for the shares to $21 from $28. Crispr’s near-term valuation driver and lead program in related blood disorders “substantially lags” more advanced competitors, Nochomovitz tells investors in a research note. The analyst believes the company’s CTX-001 is “at best equivalent” to more advanced competitors and “could have some important liabilities.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.